Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Thioridazine
Drug ID BADD_D02200
Description A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p618). Thioridazine was withdrawn worldwide in 2005 due to its association with cardiac arrythmias.
Indications and Usage For the treatment of schizophrenia and generalized anxiety disorder.
Marketing Status approved; withdrawn
ATC Code N05AC02
DrugBank ID DB00679
KEGG ID D00373
MeSH ID D013881
PubChem ID 5452
TTD Drug ID D0U1OE
NDC Product Code Not Available
UNII N3D6TG58NI
Synonyms Thioridazine | Thioridazine Hydrochloride | Thioridazine HCL | Thioridazine-Neurazpharm | Thioridazine Neurazpharm | ThioridazineNeurazpharm | Thiozine | Aldazine | Meleril | Mellaril | Melleril | Melleryl | Melleretten | Melzine | Rideril | Sonapax | Apo-Thioridazine | Apo Thioridazine | ApoThioridazine
Chemical Information
Molecular Formula C21H26N2S2
CAS Registry Number 50-52-2
SMILES CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Miosis17.02.11.002; 06.05.03.003--Not Available
Muscle rigidity17.05.02.005; 15.05.04.001--Not Available
Muscle twitching15.05.03.005--Not Available
Nasal congestion22.04.04.001--
Nausea07.01.07.001--
Neuroleptic malignant syndrome17.05.02.003; 15.05.04.015; 12.03.01.003; 08.05.01.005--Not Available
Oculogyric crisis17.01.03.002; 06.05.02.002--Not Available
Oedema08.01.07.006; 14.05.06.010--Not Available
Oedema peripheral02.05.04.007; 14.05.06.011; 08.01.07.007--
Opisthotonus17.01.03.005--Not Available
Orthostatic hypotension17.05.01.020; 24.06.03.004--Not Available
Pallor24.03.04.001; 23.03.03.031; 08.01.03.032--Not Available
Pancytopenia01.03.03.003--Not Available
Parkinsonism17.01.05.003--Not Available
Parotid gland enlargement07.06.03.001--Not Available
Photosensitivity reaction23.03.09.003--
Pregnancy test false positive13.10.05.003--Not Available
Priapism24.04.12.007; 21.03.01.005--Not Available
Rash23.03.13.001--Not Available
Rash erythematous23.03.13.029--Not Available
Rash maculo-papular23.03.13.004--
Restlessness19.11.02.002; 17.02.05.021--
Salivary hypersecretion07.06.01.009--Not Available
Seizure17.12.03.001--
Skin discolouration23.03.03.005--Not Available
Somnolence17.02.04.006; 19.02.05.003--
Stomatitis07.05.06.005--
Sudden death08.04.01.003; 02.03.04.013--
Syncope02.11.04.015; 24.06.02.012; 17.02.04.008--
Systemic lupus erythematosus23.03.02.006; 15.06.02.003; 10.04.03.004--Not Available
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene